Biopharmaceutical company Alkermes reported a net loss of $30.1m for the year to the end of December 2014.
The company, which is headquartered in Dublin and has a factory in Athlone, saw revenues increase from $596m to $619m.
It expects royalties from its portfolio of antipsychotic and multiple sclerosis drugs and other treatments to rise further this year within a range from $640m to $670m.
Alkermes chief executive Richard Pops said the results were ahead of expectations.
He said over the past two months the company has reported positive clinical data from trials of three potential treatments for manic depressive disorder, multiple sclerosis and schizophrenia.
Mr Pops described the data as "exciting clinical validation" of Alkermes' pipeline.
The three drugs are billed by Alkermes, which merged with the drug technology business previously owned by Elan in 2011, as potential blockbuster treatments meaning the company hopes each could ultimately deliver more than $1 billion in annual revenue.
